Renin-angiotensin system blockers and susceptibility to COVID-19: a multinational open science cohort study.
AuthorMorales, DR; Conover, MM; You, SC; Pratt, N; Kostka, K; Duarte-Salles, T; Fernández-Bertolín, S; Aragón, M; DuVall, SL; Lynch, K; ...
PublisherCold Spring Harbor Laboratory
University of Melbourne Author/sZhang, Lin
AffiliationMedicine Dentistry & Health Sciences
CitationsMorales, D. R., Conover, M. M., You, S. C., Pratt, N., Kostka, K., Duarte-Salles, T., Fernández-Bertolín, S., Aragón, M., DuVall, S. L., Lynch, K., Falconer, T., van Bochove, K., Sung, C., Matheny, M. E., Lambert, C. G., Nyberg, F., Alshammari, T. M., Williams, A. E., Park, R. W. ,... Suchard, M. A. (2020). Renin-angiotensin system blockers and susceptibility to COVID-19: a multinational open science cohort study.. medRxiv, https://doi.org/10.1101/2020.06.11.20125849.
Access StatusOpen Access
Open Access at PMChttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310640
INTRODUCTION: Angiotensin converting enzyme inhibitors (ACEs) and angiotensin receptor blockers (ARBs) could influence infection risk of coronavirus disease (COVID-19). Observational studies to date lack pre-specification, transparency, rigorous ascertainment adjustment and international generalizability, with contradictory results. METHODS: Using electronic health records from Spain (SIDIAP) and the United States (Columbia University Irving Medical Center and Department of Veterans Affairs), we conducted a systematic cohort study with prevalent ACE, ARB, calcium channel blocker (CCB) and thiazide diuretic (THZ) use to determine relative risk of COVID-19 diagnosis and related hospitalization outcomes. The study addressed confounding through large-scale propensity score adjustment and negative control experiments. RESULTS: Following over 1.1 million antihypertensive users identified between November 2019 and January 2020, we observed no significant difference in relative COVID-19 diagnosis risk comparing ACE/ARB vs CCB/THZ monotherapy (hazard ratio: 0.98; 95% CI 0.84 - 1.14), nor any difference for mono/combination use (1.01; 0.90 - 1.15). ACE alone and ARB alone similarly showed no relative risk difference when compared to CCB/THZ monotherapy or mono/combination use. Directly comparing ACE vs. ARB demonstrated a moderately lower risk with ACE, non-significant for monotherapy (0.85; 0.69 - 1.05) and marginally significant for mono/combination users (0.88; 0.79 - 0.99). We observed, however, no significant difference between drug- classes for COVID-19 hospitalization or pneumonia risk across all comparisons. CONCLUSION: There is no clinically significant increased risk of COVID-19 diagnosis or hospitalization with ACE or ARB use. Users should not discontinue or change their treatment to avoid COVID-19.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References